Payment overview · 2025
General Payments
$1,253.54
32 reported records · 13 companies
Healthcare provider profile · identity verified
Geoffrey Lipscomb, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FOLEY, AL · NPI 1659317345
Verified facts
What the public records show
CMS Open Payments records show Geoffrey Lipscomb, M.D. received $1,253.54 in general payments during 2025 across 32 reported records.
JAZZ PHARMACEUTICALS INC. accounted for 29.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIBERZI as an associated drug or biological on 11354 records involving 5020 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Viberzi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $372.77 | 29.7% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $221.78 | 17.7% | 5 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $143.66 | 11.5% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.83 | 10.0% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $119.99 | 9.6% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $77.25 | 6.2% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.35 | 4.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $27.91 | 2.2% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $25.13 | 2.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $25.09 | 2.0% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $24.96 | 2.0% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $20.32 | 1.6% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.50 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,103.54 | 31 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $372.77 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $221.78 | 5 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $143.66 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $124.83 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $119.99 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $77.25 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $36.30 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $36.30 | 1 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $27.91 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $25.13 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $25.09 | 1 | 2025 |
Source payment records
|
|||||
| REJOYN Normalized: rejoyn |
Device | Otsuka Pharmaceutical Development & Commercialization, Inc. | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.58 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.50 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $13.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VIBERZI open payments reported associated product |
CMS Open Payments — General Payments 11354 supporting records · 5020 recipient NPIs · example record 1201352948 |
Viberzi · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 619 | 98 |
| Zolpidem Tartrate | Zolpidem Tartrate | 456 | 79 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 353 | 64 |
| Gabapentin | Gabapentin | 263 | 65 |
| Levothyroxine Sodium | Levothyroxine Sodium | 220 | 66 |
| Celecoxib | Celecoxib | 186 | 50 |
| Amlodipine Besylate | Amlodipine Besylate | 184 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 174 | 63 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 57 |
| Metformin Hcl | Metformin Hcl | 149 | 48 |
| Lisinopril | Lisinopril | 144 | 46 |
| Alprazolam | Alprazolam | 141 | 29 |
| Losartan Potassium | Losartan Potassium | 138 | 43 |
| Oxycodone Hcl | Oxycodone Hcl | 134 | 19 |
| Omeprazole | Omeprazole | 129 | 44 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 125 | 40 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 125 | 23 |
| Tramadol Hcl | Tramadol Hcl | 119 | 28 |
| Prednisone | Prednisone | 114 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 34 |
| Simvastatin | Simvastatin | 107 | 32 |
| Meloxicam | Meloxicam | 106 | 29 |
| Furosemide | Furosemide | 101 | 41 |
| Sertraline Hcl | Sertraline Hcl | 101 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 25 |
| Clonazepam | Clonazepam | 85 | 20 |
| Buspirone Hcl | Buspirone Hcl | 84 | 24 |
| Montelukast Sodium | Montelukast Sodium | 81 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 25 |
| Pregabalin | Pregabalin | 79 | 18 |
| Valsartan | Valsartan | 79 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 77 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 24 |
| Morphine Sulfate Er | Morphine Sulfate | 73 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 69 | 54 |
| Fluoxetine Hcl | Fluoxetine Hcl | 69 | 22 |
| Meclizine Hcl | Meclizine Hcl | 69 | 17 |
| Potassium Chloride | Potassium Chloride | 67 | 22 |
| Trazodone Hcl | Trazodone Hcl | 66 | 23 |
| Promethazine Hcl | Promethazine Hcl | 64 | 17 |
| Donepezil Hcl | Donepezil Hcl | 62 | 17 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 22 |
| Mounjaro | Tirzepatide | 61 | 12 |
| Allopurinol | Allopurinol | 60 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 59 | 20 |
| Sucralfate | Sucralfate | 56 | 12 |
| Carvedilol | Carvedilol | 55 | 17 |
| Estradiol | Estradiol | 53 | 16 |
| Glipizide | Glipizide | 53 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 51 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 50 | 21 |
| Eliquis | Apixaban | 45 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 44 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 44 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 44 | 18 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 44 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 39 | 13 |
| Levofloxacin | Levofloxacin | 38 | 32 |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 33 | 12 |
| Naproxen | Naproxen | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Amoxicillin | Amoxicillin | 28 | 15 |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 26 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Memantine Hcl | Memantine Hcl | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 17 |
| Lovastatin | Lovastatin | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 19 |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 18 | 16 |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 16 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 14 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Viberzi | Eluxadoline | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,253.54 · 32 records | JAZZ PHARMACEUTICALS INC. | AIRSUPRA, BREZTRI, ETERNA, FARXIGA, INSPIRE, NUZYRA, QULIPTA, REJOYN, Sunosi, UBRELVY, VOQUEZNA, WAKIX, Wegovy, XHANCE, XYREM, XYWAV, YUPELRI, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error